These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

653 related articles for article (PubMed ID: 25043017)

  • 21. Single-cell approaches identify the molecular network driving malignant hematopoietic stem cell self-renewal.
    Shepherd MS; Li J; Wilson NK; Oedekoven CA; Li J; Belmonte M; Fink J; Prick JCM; Pask DC; Hamilton TL; Loeffler D; Rao A; Schröder T; Göttgens B; Green AR; Kent DG
    Blood; 2018 Aug; 132(8):791-803. PubMed ID: 29991556
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Physiological Jak2V617F expression causes a lethal myeloproliferative neoplasm with differential effects on hematopoietic stem and progenitor cells.
    Mullally A; Lane SW; Ball B; Megerdichian C; Okabe R; Al-Shahrour F; Paktinat M; Haydu JE; Housman E; Lord AM; Wernig G; Kharas MG; Mercher T; Kutok JL; Gilliland DG; Ebert BL
    Cancer Cell; 2010 Jun; 17(6):584-96. PubMed ID: 20541703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. β3-Adrenergic Regulation of EPC Features Through Manipulation of the Bone Marrow MSC Niche.
    Vafaei R; Nassiri SM; Siavashi V
    J Cell Biochem; 2017 Dec; 118(12):4753-4761. PubMed ID: 28513874
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Myeloproliferative neoplasia remodels the endosteal bone marrow niche into a self-reinforcing leukemic niche.
    Schepers K; Pietras EM; Reynaud D; Flach J; Binnewies M; Garg T; Wagers AJ; Hsiao EC; Passegué E
    Cell Stem Cell; 2013 Sep; 13(3):285-99. PubMed ID: 23850243
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Dysregulated megakaryocyte distribution associated with nestin
    Wang M; Feng R; Zhang JM; Xu LL; Feng FE; Wang CC; Wang QM; Zhu XL; He Y; Xue J; Fu HX; Lv M; Kong Y; Chang YJ; Xu LP; Liu KY; Huang XJ; Zhang XH
    Blood Adv; 2019 May; 3(9):1416-1428. PubMed ID: 31053569
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Functional interdependence of hematopoietic stem cells and their niche in oncogene promotion of myeloproliferative neoplasms: the 159th biomedical version of "it takes two to tango".
    Zhan H; Kaushansky K
    Exp Hematol; 2019 Feb; 70():24-30. PubMed ID: 30593829
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ptch2 loss drives myeloproliferation and myeloproliferative neoplasm progression.
    Klein C; Zwick A; Kissel S; Forster CU; Pfeifer D; Follo M; Illert AL; Decker S; Benkler T; Pahl H; Oostendorp RA; Aumann K; Duyster J; Dierks C
    J Exp Med; 2016 Feb; 213(2):273-90. PubMed ID: 26834157
    [TBL] [Abstract][Full Text] [Related]  

  • 28. JAK2-V617F and interferon-α induce megakaryocyte-biased stem cells characterized by decreased long-term functionality.
    Rao TN; Hansen N; Stetka J; Luque Paz D; Kalmer M; Hilfiker J; Endele M; Ahmed N; Kubovcakova L; Rybarikova M; Hao-Shen H; Geier F; Beisel C; Dirnhofer S; Schroeder T; Brümmendorf TH; Wolf D; Koschmieder S; Skoda RC
    Blood; 2021 Apr; 137(16):2139-2151. PubMed ID: 33667305
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The marrow stem cell niche in normal and malignant hematopoiesis.
    Kaushansky K; Zhan H
    Ann N Y Acad Sci; 2020 Apr; 1466(1):17-23. PubMed ID: 30767234
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Bone marrow mesenchymal stromal cells of patients with myeloproliferative disorders do not carry the JAK2-V617F mutation.
    Mercier F; Monczak Y; François M; Prchal J; Galipeau J
    Exp Hematol; 2009 Mar; 37(3):416-20. PubMed ID: 19135773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Different niches for stem cells carrying the same oncogenic driver affect pathogenesis and therapy response in myeloproliferative neoplasms.
    Grockowiak E; Korn C; Rak J; Lysenko V; Hallou A; Panvini FM; Williams M; Fielding C; Fang Z; Khatib-Massalha E; García-García A; Li J; Khorshed RA; González-Antón S; Baxter EJ; Kusumbe A; Wilkins BS; Green A; Simons BD; Harrison CN; Green AR; Lo Celso C; Theocharides APA; Méndez-Ferrer S
    Nat Cancer; 2023 Aug; 4(8):1193-1209. PubMed ID: 37550517
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inherited myeloproliferative neoplasm risk affects haematopoietic stem cells.
    Bao EL; Nandakumar SK; Liao X; Bick AG; Karjalainen J; Tabaka M; Gan OI; Havulinna AS; Kiiskinen TTJ; Lareau CA; de Lapuente Portilla AL; Li B; Emdin C; Codd V; Nelson CP; Walker CJ; Churchhouse C; de la Chapelle A; Klein DE; Nilsson B; Wilson PWF; Cho K; Pyarajan S; Gaziano JM; Samani NJ; ; ; Regev A; Palotie A; Neale BM; Dick JE; Natarajan P; O'Donnell CJ; Daly MJ; Milyavsky M; Kathiresan S; Sankaran VG
    Nature; 2020 Oct; 586(7831):769-775. PubMed ID: 33057200
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Bone marrow stroma-secreted cytokines protect JAK2(V617F)-mutated cells from the effects of a JAK2 inhibitor.
    Manshouri T; Estrov Z; Quintás-Cardama A; Burger J; Zhang Y; Livun A; Knez L; Harris D; Creighton CJ; Kantarjian HM; Verstovsek S
    Cancer Res; 2011 Jun; 71(11):3831-40. PubMed ID: 21512135
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A role for reactive oxygen species in JAK2 V617F myeloproliferative neoplasm progression.
    Marty C; Lacout C; Droin N; Le Couédic JP; Ribrag V; Solary E; Vainchenker W; Villeval JL; Plo I
    Leukemia; 2013 Nov; 27(11):2187-95. PubMed ID: 23558526
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Loss of Ezh2 synergizes with JAK2-V617F in initiating myeloproliferative neoplasms and promoting myelofibrosis.
    Shimizu T; Kubovcakova L; Nienhold R; Zmajkovic J; Meyer SC; Hao-Shen H; Geier F; Dirnhofer S; Guglielmelli P; Vannucchi AM; Feenstra JD; Kralovics R; Orkin SH; Skoda RC
    J Exp Med; 2016 Jul; 213(8):1479-96. PubMed ID: 27401344
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inferring the dynamics of mutated hematopoietic stem and progenitor cells induced by IFNα in myeloproliferative neoplasms.
    Mosca M; Hermange G; Tisserand A; Noble R; Marzac C; Marty C; Le Sueur C; Campario H; Vertenoeil G; El-Khoury M; Catelain C; Rameau P; Gella C; Lenglet J; Casadevall N; Favier R; Solary E; Cassinat B; Kiladjian JJ; Constantinescu SN; Pasquier F; Hochberg ME; Raslova H; Villeval JL; Girodon F; Vainchenker W; Cournède PH; Plo I
    Blood; 2021 Dec; 138(22):2231-2243. PubMed ID: 34407546
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Heterogeneity of the bone marrow niche in patients with myeloproliferative neoplasms: ActivinA secretion by mesenchymal stromal cells correlates with the degree of marrow fibrosis.
    Rambaldi B; Diral E; Donsante S; Di Marzo N; Mottadelli F; Cardinale L; Dander E; Isimbaldi G; Pioltelli P; Biondi A; Riminucci M; D'Amico G; Elli EM; Pievani A; Serafini M
    Ann Hematol; 2021 Jan; 100(1):105-116. PubMed ID: 33089365
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The regulation of normal and neoplastic hematopoiesis is dependent on microenvironmental cells.
    Kaushansky K; Zhan H
    Adv Biol Regul; 2018 Aug; 69():11-15. PubMed ID: 29970351
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Metabolic Vulnerabilities and Epigenetic Dysregulation in Myeloproliferative Neoplasms.
    Sharma V; Wright KL; Epling-Burnette PK; Reuther GW
    Front Immunol; 2020; 11():604142. PubMed ID: 33329600
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CXCL12 in early mesenchymal progenitors is required for haematopoietic stem-cell maintenance.
    Greenbaum A; Hsu YM; Day RB; Schuettpelz LG; Christopher MJ; Borgerding JN; Nagasawa T; Link DC
    Nature; 2013 Mar; 495(7440):227-30. PubMed ID: 23434756
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 33.